^
Association details:
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
Title:

Atezolizumab Plus Magrolimab, Niraparib, or Tocilizumab in Platinum-Refractory Metastatic Urothelial Carcinoma: A Phase Ib/II Open-Label, Randomized Umbrella Study

Published date:
08/31/2023
Excerpt:
The phase Ib/II MORPHEUS-UC trial (NCT03869190) is evaluating atezolizumab plus magrolimab, niraparib, or tocilizumab in platinum-refractory locally advanced or metastatic (mUC)....Trends were observed for shrinkage of PD-L1+ tumors (atezolizumab, atezolizumab plus magrolimab, atezolizumab plus tocilizumab)…
DOI:
10.1158/1078-0432.CCR-23-0798
Trial ID: